EUCTR2014-002121-35-DE进行中（未招募）1 期
A Phase 2, Open Label Study to Evaluate The Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination (FDC) Tablet for 12 or 24 Weeks in Kidney Transplant Recipients with Chronic HCV Infection
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects must meet all of the following inclusion criteria to be eligible for participation in this study.
- •1)Willing and able to provide written informed consent.
- •2)Male or female, age = 18 years.
- •3)Body mass index (BMI) = 18 kg/m2
- •4)Have received a kidney transplant more than 6 months before the Baseline visit
- •5)HCV RNA = the lower limit of quantitation (15 IU/mL) at Screening
- •6)HCV genotype 1 or 4 at Screening as determined by the Central Laboratory. Any non definitive results will exclude the subject from study participation.
- •7)Chronic HCV infection (= 6 months) documented by prior medical history or liver biopsy
- •1)HCV treatment status of one of the following:
- •a) HCV Treatment-naïve: No prior exposure to any IFN, RBV, or other approved or experimental HCV-specific DAA agent
- •b) HCV Treatment-Intolerant: Subjects that discontinued HCV treatment due to development or significant worsening of a treatment related adverse event
- •c) HCV Treatment-Experienced: Virologic failure during or after treatment. Subjects in this category must not have discontinued prior therapy due to an adverse event.
- •8)Have demonstrated absence of cirrhosis or have compensated cirrhosis:
- •a)Cirrhosis is defined as any one of the following:
- •i)Liver biopsy showing cirrhosis (e.g., Metavir score = 4 or Ishak score = 5)
- •ii)Fibroscan® (in countries where locally approved) showing cirrhosis or results > 12.5 kPa
- •iii)FibroTest® score of > 0.75 AND an AST: platelet ratio index (APRI) of > 2 during Screening
- •b)Absence of cirrhosis is defined as no evidence of cirrhosis and any one of the following:
- •i)Liver biopsy within 2 years of Screening showing absence of cirrhosis
- •ii)Fibroscan® (in countries where locally approved) within 6 months of Baseline/Day 1 with a result of = 12.5 kPa
- •iii)FibroTest® score of = 0.48 AND APRI of = 1 during Screening
- •9)Liver imaging within 6 months prior to Baseline/Day 1 is required in subjects with cirrhosis to exclude hepatocellular carcinoma (HCC)
- •10)Screening ECG without clinically significant abnormalities
- •11)Subjects must have the following laboratory parameters at screening:
- •a)ALT = 10 x the upper limit of normal (ULN)
- •b)AST = 10 x ULN
- •c)Direct bilirubin ? 1.5 x ULN
- •d)Platelets > 50,000 cells/µL
- •e)HbA1c = 10%
- •f)Creatinine clearance (CLcr) = 40 mL /min, as calculated by the Cockcroft Gault equation {2202}
- •g)Hemoglobin = 10 g/dL
- •h)Albumin = 3g/dL
- •i)INR = 1.5 x ULN unless subject has known hemophilia or is stable on an anticoagulant regimen affecting INR.
- •12)Females of childbearing potential (as defined in Appendix 4) must have a negative serum pregnancy test at Screening and a negative urine pregnancy test on Baseline/Day 1 prior to enrollment.
- •13)Male subjects and female subjects of childbearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of contraception as described in Appendix 4.
- •14)Male subjects must agree to refrain from sperm donation from the date of screening until 90 days after their last dose of study drug.
- •15)Subject must be of generally good health, with the exception of chronic HCV infection and renal disease, as determined by the Investigator.
- •16)Subject must be able to comply with the dosing instructions for study drug administration and able to complete the study schedule of assessments, including all required post treatment visits.
- •Are the trial subjects under 18? no
- •Number of subjects for this
排除标准
- •Subjects who meet any of the following exclusion criteria will not to be eligible for participation in this study.
- •1) Current or prior history of any of the following:
- •a) Clinically-significant illness (other than HCV and kidney disease) or any other major medical disorder that may interfere with subject treatment, assessment or compliance with the protocol; subjects currently under evaluation for a potentially clinically significant illness (other than HCV) are also excluded.
- •b) Gastrointestinal disorder or post-operative condition that could interfere with the absorption of the study drug.
- •c) Difficulty with blood collection and/or poor venous access for the purposes of phlebotomy.
- •d) Clinical hepatic decompensation (i.e., ascites, encephalopathy or variceal hemorrhage). The presence of varices will be accepted
- •e) Solid organ transplantation other than kidney.
- •f) Significant cardiac disease.
- •g) Psychiatric hospitalization and/or suicide attempt within the last 2 years. Subjects with psychiatric illness (without the prior mentioned conditions) that is well controlled on a stable treatment regimen for at least 6 months prior to enrollment or has not required medication in the last 6 months may be included.
- •h) Malignancy within 5 years prior to screening, with the exception of specific cancers that are entirely cured by surgical resection (basal cell skin cancer, etc.). Subjects under evaluation for possible malignancy are not eligible.
- •i) Significant drug allergy (such as anaphylaxis or hepatotoxicity).
- •2) Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV).
- •3) Pregnant or nursing female or male with pregnant female partner.
- •4) Chronic liver disease of a non HCV etiology (e.g., hemochromatosis, Wilson’s disease, alpha 1 antitrypsin deficiency, cholangitis).
- •5) In the opinion of the Investigator, clinically-relevant alcohol or drug abuse within 12 months of Screening. A positive drug screen during Screening will exclude subjects unless it can be explained by a prescribed medication; the diagnosis and prescription must be approved by the Investigator.
- •6) Planned or anticipated second kidney transplant.
- •7) Use of any prohibited concomitant medications as described in Section 5.4 .
- •8) Known hypersensitivity to LDV, SOF, or formulation excipients.
研究者
相似试验
进行中（未招募）
1 期
An international study to assess the safety and efficacy of a combination of new investigational drugs in hepatitis C virus infected patients with advanced liver disease or require treatment after kidney transplantation.Chronic Genotype 1 and Genotype 4 Hepatitis C Virus InfectionMedDRA version: 17.0Level: LLTClassification code 10019751Term: Hepatitis C virusSystem Organ Class: 100000004848EUCTR2014-002121-35-ITGilead Sciences, Inc.150
进行中（未招募）
1 期
An international study to assess the safety and efficacy of a combination of new investigational drugs in hepatitis C virus infected patients with advanced liver disease or require treatment after kidney transplantation.Chronic Genotype 1 and Genotype 4 Hepatitis C Virus InfectionMedDRA version: 18.1Level: LLTClassification code 10019751Term: Hepatitis C virusSystem Organ Class: 100000004848EUCTR2014-002121-35-ATGilead Sciences, Inc.150
进行中（未招募）
1 期
A study to understand the safety and effectiveness of switching to a new drug called Vemlidy from an existing drug called Viread or other oral antiviral treatments drugs for the treatment of long term hepatitis B infection in subjects with renal and/or hepatic impairmentChronic Hepatitis BMedDRA version: 20.0Level: PTClassification code 10008910Term: Chronic hepatitis BSystem Organ Class: 10021881 - Infections and infestationsEUCTR2016-004625-16-GBGilead Sciences, Inc.120
进行中（未招募）
1 期
A study to understand the safety and effectiveness of switching to a new drug called Vemlidy from an existing drug called Viread or other oral antiviral treatments drugs for the treatment of long term hepatitis B infection in subjects with renal and/or hepatic impairmentChronic Hepatitis BMedDRA version: 20.1Level: PTClassification code 10008910Term: Chronic hepatitis BSystem Organ Class: 10021881 - Infections and infestationsEUCTR2016-004625-16-ITGILEAD SCIENCES INCORPORATED120
进行中（未招募）
1 期
Pembrolizumab in combination with vibostolimab in relapsed or refractory hematologic malignanciesEUCTR2021-001700-15-ESMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.180